Gensight Biologics SA Stock
€0.30
Your prediction
Gensight Biologics SA Stock
Pros and Cons of Gensight Biologics SA in the next few years
Pros
Cons
Performance of Gensight Biologics SA vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | -1.800% | 5.820% | -8.953% | -56.395% | -32.280% | -96.186% | -79.675% |
Celsion Corp. | -6.310% | -11.864% | 4.000% | -7.965% | 74.790% | -92.076% | -95.373% |
India Globalization Capital | -1.040% | -2.564% | 10.465% | 39.706% | 45.038% | -77.095% | -64.232% |
Protara Therapeutics Inc. | -3.740% | 0.980% | 15.084% | -12.712% | 21.893% | -68.550% | - |
Comments
News
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Launches Newsletter for Retail Investors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal